Condition: GERD · Gastroesophageal Reflux · Gastroparesis · Sponsor: Jose Cocjin
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
This description comes directly from the study's public registry record.
Corey Schurman, MA, CCRC · 816-302-3076 · crschurman@cmh.edu
Always discuss trial participation with your own doctor first.
| Children's Mercy Hospitals and Clinics | Kansas City, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04699591